Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals has reported results from the Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
Subscribe to our email newsletter
The randomized, placebo-controlled single-dose escalation Phase I study enrolled patients with ATTR into seven sequential cohorts of increasing doses ranging from 0.01 to 1.0mg/kg.
Patients administered with ALN-TTR01 showed significant reductions in serum TTR protein levels, including both wild-type and mutant TTR protein.
ALN-TTR01 also demonstrated a dose-dependent reduction in serum TTR levels with a mean reduction of 38% at approximately day 7 to 10 in the 1mg/kg group.
Alnylam Pharmaceuticals Clinical Research senior director Jared Gollob said the Phase I data from the ALN-TTR01 clinical study demonstrate rapid, dose-dependent, and durable lowering of TTR protein levels after a single dose in ATTR patients.
"We believe these data with ALN-TTR01 provide key human proof of concept as we advance ALN-TTR02 as our ‘go-to-market’ RNAi therapeutic for the treatment of ATTR, a debilitating orphan genetic disease," Gollob added.
The company plans to commence a Phase II multi-dose study of ALN-TTR02 in the second half of 2012.